Preclinical and Clinical evaluation of the effect on oral administration of PARANGI KASAYAM along with external application of VARMAM THERAPHY in the management of INFANTILE HEMIPLEGIA in children

Preclinical and clinical evaluation of the effect on oral administration of PARANGI KASAYAM along with external application of VARMAM THERAPHY in the management of BALAR PAKKA VATHAM ( INFANTILE HEMIPLEGIA)in children.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/11/046972

Enrollment

Registered

2022-11-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G819- Hemiplegia, unspecified

Interventions

Intervention1: PARANGI KASAYAM (ORAL ADMINISTRATION): Should be administrated orally twice a day after food for 48 days. Dosage : 2-4 years : 10 ml 4-7 years : 15 ml 7-12 years :

Eligibility

Inclusion criteria

Inclusion criteria: Stiffness and weekness in muscles on one side of the body Pain Muscle spasm Delayed milestones Difficulty with walking and balance

Exclusion criteria

Exclusion criteria: Children below 2 years Children above 12 years Congenoital cardiac failure Infantile hemiplegia with associated congenital abnormalities Infantile hemiplegia with co-morbidities like mental retardation and muscular dystrophy

Design outcomes

Primary

Measure	Time frame
To access the effectiveness of PARANGI KASAYAM AND VARMAM THERAPHY in the management of BALAR PAKKA VATHAM in children by using GMFCS, MACS, EDACS rating scale to improve their mobility and regain their functional independenceTimepoint: 48 DAYS	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr D K Soundararajan MDs

dr.dks2012@gmail.com9442048801

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026